 |
(2,2-diphenyl-tetrahydro-furan-3-yl-methyl)-dimethylamine hydrochloride |
|---|---|
| Trade Name | |
| Orphan Indication | Rett like syndrome |
| USA Market Approval | USA |
| USA Designation Date | 2016-05-18 00:00:00 |
| Sponsor | Anavex Life Sciences Corporation;51 West 52nd Street, 7th Floor;New York, New York, 10019 |
